Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?

Eye (Basingstoke)

Volumn 27, Issue 1, 2013, Pages 56-64

  Ross, A H ^a   Donachie, P H J ^b   Sallam, A ^a   Stratton, I M ^b   Mohamed, Q ^a   Scanlon, P H ^a,b   Kirkpatrick, J N ^a   Johnston, R L ^a  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

agerelated macular degeneration; neovascular; ranibizumab; visual acuity

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CATARACT EXTRACTION; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; VISUAL ACUITY;

EID: 84872228135     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.225     Document Type: Article

References (25)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291(15): 1900-1901. (Pubitemid 38509505)
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431. (Pubitemid 44511557)
3. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432-1444. (Pubitemid 44511558)
4. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116(1): 57-65; e55-57-65.e55.
5. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4): 566-583.
6. Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina (Philadelphia, Pa) 2011; 31(1): 26-30.
7. Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009; 148(3): 409-413.
8. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UEK. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009; 147(5): 831-837.
9. Bandukwala T, Muni RH, Schwartz C, Eng KT, Kertes PJ. Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. Can J Ophthalmol 2010; 45(6): 590-595.
10. Kumar A, Sahni JN, Stangos AN, Campa C, Harding SP. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. Br J Ophthalmol 2011; 95(4): 530-533.
11. Kang S, Roh Y-J. One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. Jpn J Ophthalmol 2009; 53(4): 389-395.
12. Rotsos T, Patel PJ, Chen FK, Tufail A. Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration. Clin Ophthalmol (Auckland, NZ) 2010; 4: 1271-1275.
13. Michalova K, Wickremasinghe SS, Tan TH, Chang A, Harper CA, Downie JA et al. Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. Eye (London, England) 2009; 23(8): 1633-1640.
14. Dadgostar H, Ventura AACM, Chung JY, Sharma S, Kaiser PK. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009; 116(9): 1740-1747.
15. Arias L, Roman I, Masuet-Aumatell C, Rubio MJ, Caminal JM, Catala J et al. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Retina (Philadelphia, Pa) 2011; 31(7): 1261-1267.
16. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010; 117(11): 2134-2140.
17. StataCorp. Stata Statistical Software: Release 11. StataCorp: College Station, TSL, 2009.
18. Martin DF, Maguire MG, Ying G-s, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897-1908.
19. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119(7): 1388-1398.
20. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119(7): 1399-1411.
21. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114(2): 246-252. (Pubitemid 46172497)
22. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144(6): 850-857.
23. Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye (London, England) 2011; 25(12): 1617-1621.
24. Shona O, Gupta B, Vemala R, Sivaprasad S. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. Clin Exper Ophthalmol 2011; 39(1): 5-8.
25. Querques G, Azrya S, Martinelli D, Berboucha E, Feldman A, Pece A et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 2010; 94(3): 292-296.